Pulse Biosciences (NASDAQ: PLSE) CCO sells shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of $1.53 per share each day, converting them into 20,000 common shares per day.
On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of $21.45, $23.52, and $25.20 per share, respectively, leaving 43,298 common shares held directly after each day’s sale. These trades were carried out under a Rule 10b5‑1 trading plan adopted on May 14, 2025.
Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of $1.53 per share, originally granted on September 23, 2022 for up to 450,000 shares, with 25% vesting on each anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 60,000 shares ($1,403,400)
Net Sell
9 txns
Insider
Danahy Kevin Patrick
Role
Chief Commercial Officer
Sold
60,000 shs ($1.40M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $1.53 | $31K |
| Sale | Common Stock | 20,000 | $25.20 | $504K |
| Exercise | Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $1.53 | $31K |
| Sale | Common Stock | 20,000 | $23.52 | $470K |
| Exercise | Stock Option (right to buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $1.53 | $31K |
| Sale | Common Stock | 20,000 | $21.45 | $429K |
Holdings After Transaction:
Stock Option (right to buy) — 365,000 shares (Direct);
Common Stock — 63,298 shares (Direct)
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $21.00 to $23.22 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $26.08 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.36 to $26.36 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range. Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.
FAQ
What insider transactions did PLSE’s Chief Commercial Officer report?
Kevin Patrick Danahy exercised stock options and sold common shares in Pulse Biosciences. Over February 9–11, 2026, he exercised 20,000 options per day at $1.53 and sold 20,000 shares per day in open-market transactions at progressively higher weighted average prices.
At what prices did the PLSE insider sell common stock?
The reported sales used weighted average prices per share. On February 9, 10, and 11, 2026, Kevin Patrick Danahy sold 20,000 Pulse Biosciences shares each day at $21.45, $23.52, and $25.20, respectively, as disclosed in the Form 4 transaction table.
What stock options in PLSE does the Chief Commercial Officer still own?
Following the option exercises, Kevin Patrick Danahy directly holds 365,000 stock options for Pulse Biosciences common stock. These options have a $1.53 exercise price, were granted on September 23, 2022, and were originally for up to 450,000 shares with annual 25% vesting.
Were the PLSE insider trades under a Rule 10b5-1 trading plan?
Yes. The Form 4 states that all the reported transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Kevin Patrick Danahy on May 14, 2025, and pre-arranged the timing and amounts of his trades in Pulse Biosciences shares.
What do the weighted average prices in the PLSE Form 4 mean?
The prices reported for the sales are weighted average prices per share. Footnotes explain that actual sale prices ranged within specified bands and that, upon request, the insider will provide detailed breakdowns of the number of shares sold at each individual price within those ranges.